5.66
0.12 (2.17%)
| Penutupan Terdahulu | 5.54 |
| Buka | 5.55 |
| Jumlah Dagangan | 90,938 |
| Purata Dagangan (3B) | 1,139,850 |
| Modal Pasaran | 568,056,000 |
| Harga / Jualan (P/S) | 651.62 |
| Harga / Buku (P/B) | 2.95 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2026 |
| Margin Operasi (TTM) | -1,621.58% |
| EPS Cair (TTM) | -1.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -100.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.72% |
| Nisbah Semasa (MRQ) | 9.08 |
| Aliran Tunai Operasi (OCF TTM) | -56.39 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -30.34 M |
| Pulangan Atas Aset (ROA TTM) | -41.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -71.90% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Shattuck Labs, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| Persekitaran Makro | -0.8 |
| AI Insight | NA |
| Purata | -0.83 |
|
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 14.36% |
| % Dimiliki oleh Institusi | 64.06% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Redmile Group, Llc | 30 Jun 2026 | 6,892,033 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |